-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Addus HomeCare’s (ADUS) Texas Reimbursement Focus Quietly Redefining Its Personal Care Investment Story?

Simply Wall St·02/13/2026 06:40:22
Listen to the news
  • Addus HomeCare recently announced it released its fourth-quarter and full-year 2025 results on February 23, 2026, followed by a management conference call and webcast on February 24 to discuss performance and outlook with investors.
  • What stands out is how this earnings release coincides with growing attention on the company’s Personal Care operations, where reimbursement changes and acquisition activity have become central to its business profile.
  • Next, we’ll examine how expectations around Texas reimbursement rate increases and Personal Care growth may influence Addus HomeCare’s existing investment narrative.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

Addus HomeCare Investment Narrative Recap

To own Addus HomeCare, you need to believe in the durability of its Medicaid-funded Personal Care model and its ability to balance reimbursement changes with cost pressures. Right now, a key short term catalyst is how Texas rate increases and related Personal Care growth show up in reported margins, while the biggest risk remains exposure to shifting government reimbursement policies. The latest earnings timing and analyst commentary do not appear to materially change those core drivers.

The most relevant recent announcement is the upcoming fourth quarter and full year 2025 earnings release and conference call on February 23–24, 2026. This event will put a spotlight on how Texas reimbursement changes and recent Personal Care acquisitions, including transactions in South Texas, are affecting segment mix and profitability. For investors focused on Personal Care as the primary earnings engine, the call may provide important detail on whether current expectations for rate supported growth still look reasonable.

Yet beneath the optimism around Texas rate gains, investors should be aware of how heavily Addus still depends on Medicaid funding and what happens if those budgets...

Read the full narrative on Addus HomeCare (it's free!)

Addus HomeCare's narrative projects $1.7 billion revenue and $136.9 million earnings by 2028. This requires 10.1% yearly revenue growth and a $53.9 million earnings increase from $83.0 million today.

Uncover how Addus HomeCare's forecasts yield a $142.91 fair value, a 27% upside to its current price.

Exploring Other Perspectives

ADUS 1-Year Stock Price Chart
ADUS 1-Year Stock Price Chart

Some of the lowest ranked analysts see more risk here, despite the Texas rate story, penciling in revenue of about US$1.6 billion and earnings of roughly US$122.7 million by 2028, which reflects a far more cautious view of reimbursement stability and margin pressure than the more optimistic narrative you have just read.

Explore 4 other fair value estimates on Addus HomeCare - why the stock might be worth as much as 100% more than the current price!

Build Your Own Addus HomeCare Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Addus HomeCare research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • Our free Addus HomeCare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Addus HomeCare's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.